Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients

Table 1 Summary of demographic and clinical characteristics at baseline of chronic hepatitis B patients on tenofovir alafenamide or entecavir therapy

Characteristic	TAF, n = 214	ETV, n = 122	P value
Age in yr	43.38 ± 10.42	49.96 ± 11.82	0.001
Male	158 (73.83)	96 (78.69)	0.387
BMI in kg/m2	22.97 ± 2.93	23.78 ± 3.30	0.152
Smoking	16 (7.48)	15 (12.30)	0.203
Drinking	13 (6.07)	14 (11.48)	0.123
ALT in U/L	36.60 ± 36.87	30.44 ± 20.00	0.089
AST in U/L	28.01 ± 26.41	24.50 ± 13.58	0.172
logHBsAg in ng/mL	3.07 ± 0.92	3.04 ± 0.84	0.787
logDNA in IU/mL	1.94 ± 1.23	1.86 ± 1.05	0.56
CREA in μmol/L	73.68 ± 15.87	74.82 ± 16.78	0.535
UA in μmol/L	353.52 ± 89.10	357.23 ± 84.29	0.708
GFR in mL/min	103.48 ± 15.01	97.86 ± 14.17	0.001
CK in U/L	157.23 ± 444.75	122.91 ± 71.31	0.401
FBG in mmol/L	5.18 ± 0.80	5.52 ± 1.61	0.011
Concurrent diseases
Hypertension	17 (7.94)	21 (17.21)	0.016
DM	20 (9.35)	13 (10.66)	0.844
NAFLD	75 (35.05)	32 (26.23)	0.122
Cirrhosis	54 (25.23)	50 (40.98)	0.004

Data are presented as n (%). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CK: Creatine kinase; CREA: Creatinine; DM: Diabetes mellitus; ETV: Entecavir; FBG: Fasting blood-glucose; GFR: Glomerular filtration rate; HBsAg: Hepatitis B surface antigen; NAFLD: nonalcoholic fatty liver disease; TAF: Tenofovir alafenamide; UA: Uric acid.